{
  "screened_ideas": [
    {
      "date": "2026-01-01",
      "ticker": "APTV",
      "company": "Aptiv PLC",
      "archetype": "spinoff",
      "event_id": "EVT-2026-022",
      "kill_screens_passed": true,
      "passed_screens": [
        {
          "screen": "Beneish M-Score",
          "value": -2.88,
          "threshold": -1.78,
          "operator": "<=",
          "result": "PASS - Low manipulation risk (best historical performance)",
          "source": "GuruFocus"
        },
        {
          "screen": "Altman Z-Score",
          "value": 2.39,
          "threshold": 1.81,
          "operator": ">=",
          "result": "PASS - Grey zone (1.81-2.99), moderate financial health",
          "source": "Macroaxis"
        }
      ],
      "result": "WATCHLIST",
      "watchlist_file": "universe/watchlist/APTV.md",
      "next_step": "Run 'score' skill to complete analysis",
      "financial_summary": {
        "market_cap": "$16.44B",
        "current_price": "$76.09",
        "revenue_ttm": "$20.15B",
        "net_income_ttm": "$295M",
        "pe_ratio": 58.43,
        "forward_pe": 9.60,
        "beta": 1.52
      },
      "spinoff_details": {
        "spinco": "Cyprium (EDS wiring business)",
        "distribution_date": "2026-01-02",
        "regular_trading_begins": "2026-01-05",
        "expected_completion": "Q1 2026 (by March 31)",
        "optimal_entry_window": "Days 30-60 post-distribution (Feb 1 - March 3, 2026)",
        "rationale": "Separation of commodity EDS business from high-growth ADAS/software RemainCo"
      },
      "notes": "Distribution occurs Jan 2, 2026. Framework suggests waiting for days 30-60 entry window to exploit forced index selling. Parent spent 6+ months preparing (announced earlier in 2025), correlates with +50% first-year returns."
    },
    {
      "date": "2026-01-01",
      "ticker": "SOAR",
      "company": "Volato Group, Inc.",
      "archetype": "merger_arb",
      "event_id": "EVT-2026-028",
      "kill_screens_passed": false,
      "failed_screens": [
        {
          "screen": "Beneish M-Score",
          "value": 6.62,
          "threshold": -1.78,
          "operator": "<=",
          "result": "SEVERE FAIL - Score of 6.62 >> -1.78 threshold, indicates likely earnings manipulation",
          "source": "GuruFocus / Web search"
        },
        {
          "screen": "Altman Z-Score",
          "value": -3.9,
          "threshold": 1.81,
          "operator": ">=",
          "result": "SEVERE FAIL - Score of -3.9 << 1.81 threshold, extreme bankruptcy risk",
          "source": "GuruFocus / Web search",
          "context": "Z-Score below -1.0 indicates severe distress. SOAR's -3.9 is catastrophic."
        }
      ],
      "result": "PASS",
      "reason": "Failed BOTH universal kill screens catastrophically. M-Score of 6.62 suggests earnings manipulation. Z-Score of -3.9 indicates extreme financial distress and imminent bankruptcy risk.",
      "financial_red_flags": {
        "market_cap": "$4.77M (micro-cap)",
        "current_price": "$0.64 (down 18.99% on Dec 31)",
        "52_week_range": "$0.618 - $7.36 (91% decline from high)",
        "revenue_decline": "From $96.7M (2022) to $46.3M (2024) = -52% decline",
        "stockholders_equity": "-$16.3M (negative equity)",
        "net_income_quality": "Deeply negative, unsustainable",
        "going_concern_risk": "High probability of bankruptcy within 2 years"
      },
      "merger_details": {
        "acquirer": "M2i Global (critical minerals company)",
        "deal_structure": "All-stock reverse merger",
        "ownership_post_merger": "M2i shareholders 85%, SOAR shareholders 15%",
        "shares_issued": "57,718,662 new Class A shares",
        "shareholder_vote_date": "2026-02-26",
        "expected_close": "Q1 2026",
        "deal_rationale": "M2i using SOAR as reverse merger vehicle to go public",
        "current_soar_price": "$0.64 (as of Dec 31, 2025)"
      },
      "framework_assessment": "This is NOT a traditional merger arb opportunity. It's a reverse merger where a struggling aviation company (SOAR) with catastrophic financials is being used by M2i Global as a shell to go public. Both universal kill screens failed by wide margins. SOAR shareholders are being massively diluted (85% to M2i). Extreme bankruptcy risk makes this uninvestable.",
      "additional_concerns": [
        "Revenue collapsed 52% from 2022 to 2024",
        "Negative stockholders' equity signals insolvency",
        "Stock down 91% from 52-week high",
        "Micro-cap ($4.77M) with severe liquidity issues",
        "M-Score of 6.62 is among the worst possible scores",
        "Aviation business model appears fundamentally broken"
      ]
    },
    {
      "date": "2026-01-01",
      "ticker": "FDX",
      "company": "FedEx Corporation",
      "archetype": "spinoff",
      "event_id": "EVT-2026-024",
      "kill_screens_passed": true,
      "passed_screens": [
        {
          "screen": "Beneish M-Score",
          "value": -2.62,
          "threshold": -1.78,
          "operator": "<=",
          "result": "PASS - No manipulation concerns, strong score",
          "source": "GuruFocus / Web search"
        },
        {
          "screen": "Altman Z-Score",
          "value": 2.55,
          "threshold": 1.81,
          "operator": ">=",
          "result": "PASS - Grey zone (1.81-2.99), some financial stress but acceptable",
          "source": "GuruFocus",
          "context": "Historical range: 1.98-3.54, median 2.59. Piotroski F-Score of 7 indicates strong fundamentals."
        }
      ],
      "result": "WATCHLIST",
      "watchlist_file": "universe/watchlist/FDX.md",
      "next_step": "Run 'score' skill to complete analysis",
      "framework_fit_assessment": "MODERATE - Large-cap size and 6-month wait reduce framework fit vs smaller, imminent catalysts",
      "financial_summary": {
        "market_cap": "$67.92B (large-cap)",
        "current_price": "$288.86",
        "revenue_ttm": "$90.09B",
        "net_income_ttm": "$4.33B",
        "pe_ratio": 15.92,
        "forward_pe": 14.83,
        "dividend_yield": "2.01%",
        "analyst_consensus": "Buy with $294.68 target (+2%)"
      },
      "spinoff_details": {
        "spinco": "FedEx Freight (LTL business)",
        "spinco_ticker": "FDXF",
        "distribution_date": "2026-06-01 (targeted)",
        "expected_completion": "June 2026",
        "optimal_entry_window": "Days 30-60 post-distribution (July 1 - Aug 1, 2026)",
        "rationale": "Separation of asset-light express/e-commerce (RemainCo) from capital-intensive LTL freight (SpinCo)",
        "it_investment": "$600M in IT infrastructure preparation",
        "spinco_ceo": "John Smith (internal hire, disappointed Wall Street)"
      },
      "investment_considerations": {
        "positives": [
          "Clean strategic rationale (express vs LTL separation)",
          "Freight could command LTL peer multiples as standalone",
          "Freight becomes potential takeover target",
          "Strong analyst support (Buy consensus)",
          "Significant IT investment ($600M) signals serious preparation"
        ],
        "concerns": [
          "Large-cap $67.92B (framework designed for smaller opportunities)",
          "LTL market weakness: Freight guidance downgraded to 'flat or slightly down'",
          "Wall Street disappointed with internal CEO hire vs external catalyst",
          "6-month wait to distribution (vs APTV tomorrow)",
          "Z-Score 2.55 in gray zone indicates some financial stress",
          "No clear evidence of 6+ month preparation window that correlates with +50% returns"
        ]
      },
      "notes": "Distribution targeted June 2026. Framework suggests waiting for days 30-60 entry window (July-August 2026). Large-cap size reduces framework fit. Monitor LTL market conditions and Freight segment performance in coming quarters."
    },
    {
      "date": "2026-01-01",
      "ticker": "HON",
      "company": "Honeywell International Inc.",
      "archetype": "spinoff",
      "event_id": "EVT-2026-013",
      "kill_screens_passed": true,
      "passed_screens": [
        {
          "screen": "Beneish M-Score",
          "value": -2.56,
          "threshold": -1.78,
          "operator": "<=",
          "result": "PASS - Strong score, no manipulation concerns",
          "source": "GuruFocus / Web search"
        },
        {
          "screen": "Altman Z-Score",
          "value": 3.53,
          "threshold": 1.81,
          "operator": ">=",
          "result": "PASS - Safe zone (>3.0), excellent financial health",
          "source": "GuruFocus / Web search",
          "context": "ROE 34.52%, operating margin 21%, EBITDA margin 25.19%"
        }
      ],
      "result": "WATCHLIST",
      "watchlist_file": "universe/watchlist/HON.md",
      "next_step": "Run 'score' skill to complete analysis",
      "framework_fit_assessment": "WEAK - Mega-cap size ($123.86B) makes this institutional/widely-analyzed vs idiosyncratic framework focus",
      "financial_summary": {
        "market_cap": "$123.86B (mega-cap)",
        "current_price": "$195.09",
        "revenue_ttm": "$40.67B",
        "net_income_ttm": "$6.13B",
        "pe_ratio": 20.59,
        "forward_pe": 19.00,
        "dividend_yield": "2.44%",
        "roe": "34.52%",
        "operating_margin": "21%",
        "analyst_consensus": "Buy with $238.92 target (+22.5%)"
      },
      "spinoff_details": {
        "spinco_1": "Honeywell Aerospace ($15B revenue, pure-play supplier)",
        "spinco_2": "Possibly Automation (~$94B estimated value)",
        "previous_spinoff": "Solstice Advanced Materials (completed Oct 30, 2025)",
        "distribution_date": "2026-09-30 (estimated, 2H 2026 targeted)",
        "expected_completion": "Second half 2026",
        "optimal_entry_window": "Days 30-60 post-distribution (Oct-Nov 2026)",
        "rationale": "Conglomerate breakup: Aerospace + Automation pursue distinct strategies",
        "activist_involvement": "Elliott Investment Management took major stake, pushing separation"
      },
      "investment_considerations": {
        "positives": [
          "Activist catalyst (Elliott Investment Management)",
          "Proven spinoff execution (Solstice completed Oct 2025)",
          "Stellar financials (Z-Score 3.53, ROE 34.52%)",
          "Aerospace becomes one of largest pure-play suppliers globally",
          "Automation exposed to digital transformation megatrend",
          "Strong analyst support (+22.5% upside to target)"
        ],
        "concerns": [
          "Mega-cap $123.86B (framework designed for $500M-$20B opportunities)",
          "9-month wait to distribution (vs APTV tomorrow, FDX 6 months)",
          "Two spinoffs complexity (Aerospace + Automation vs typical single)",
          "Already announced Feb 2025 (market may have priced in unlock)",
          "Conglomerate discount may take years to fully re-rate",
          "Widely-followed institutional situation, not overlooked opportunity"
        ]
      },
      "framework_limitation_note": "This screening reveals a potential framework boundary: Mega-cap spinoffs (>$100B) are widely-analyzed institutional situations that don't fit the idiosyncratic framework's focus on underappreciated, smaller special situations. Consider adding market cap ceiling to screening criteria.",
      "notes": "Distribution targeted 2H 2026 (Sept-Oct estimated). Framework suggests days 30-60 entry window (Oct-Nov 2026). Mega-cap size significantly reduces framework fit - this is an institutional play, not an overlooked catalyst. Worth monitoring for educational purposes but low priority vs smaller opportunities."
    },
    {
      "date": "2026-01-01",
      "ticker": "SPGI",
      "company": "S&P Global Inc.",
      "archetype": "spinoff",
      "event_id": "EVT-2026-023",
      "kill_screens_passed": true,
      "passed_screens": [
        {
          "screen": "Beneish M-Score",
          "value": -2.53,
          "threshold": -1.78,
          "operator": "<=",
          "result": "PASS - No manipulation concerns",
          "source": "GuruFocus",
          "note": "Re-verified from 2025-12-30 screening (was -2.44, now -2.53)"
        },
        {
          "screen": "Altman Z-Score",
          "value": 5.10,
          "threshold": 1.81,
          "operator": ">=",
          "result": "PASS - Safe zone (>3.0), excellent financial health",
          "source": "SEC XBRL (from 2025-12-30 screening)",
          "note": "Maintained strong Z-Score from prior screening"
        }
      ],
      "result": "WATCHLIST (RE-ANALYZED)",
      "watchlist_file": "universe/watchlist/SPGI.md",
      "next_step": "Previously scored 7.5 (CONDITIONAL) - monitor Form 10 filing when available",
      "framework_fit_assessment": "WEAK - Mega-cap ($158.24B), widely-analyzed, already scored CONDITIONAL (7.5)",
      "previous_screening": {
        "date": "2025-12-30",
        "price": "$527.69",
        "final_score": 7.5,
        "decision": "CONDITIONAL"
      },
      "financial_summary": {
        "market_cap": "$158.24B (mega-cap)",
        "current_price": "$522.59 (down -1% from prior screening)",
        "revenue_ttm": "$15.01B",
        "net_income_ttm": "$4.22B",
        "pe_ratio": 38.03,
        "forward_pe": 27.10,
        "dividend_yield": "0.73%",
        "analyst_consensus": "Strong Buy with $609.31 target (+16.59%)"
      },
      "spinoff_details": {
        "spinco": "S&P Global Mobility (CARFAX, automotive data/analytics)",
        "announced_date": "2025-04-29",
        "mobility_revenue": "$1.6B (11% of total revenue)",
        "mobility_growth": "8% YoY in 2024",
        "distribution_date": "Late 2026 (Oct-Nov estimated)",
        "timeline": "12-18 months from April 2025 announcement",
        "optimal_entry_window": "Days 30-60 post-distribution (Nov-Dec 2026)",
        "rationale": "Mobility gets auto data/analytics multiples; RemainCo focuses on high-margin ratings/indices",
        "value_unlock_estimate": "$5B-$8B (3-5% of current market cap)",
        "remainco_margin_target": "52% operating margins by 2029",
        "tax_treatment": "Expected to be tax-free to shareholders",
        "executive_team": "SpinCo leadership already appointed (CPO, CLO, CIO)"
      },
      "investment_considerations": {
        "positives": [
          "Strong financials (Z-Score 5.10, excellent margins)",
          "Clear value unlock estimate ($5B-$8B)",
          "Tax-free structure expected",
          "RemainCo margin expansion to 52% by 2029",
          "Executive team in place for SpinCo",
          "Strong analyst support (+16.59% upside to target)"
        ],
        "concerns": [
          "Mega-cap $158.24B (widely-analyzed institutional situation)",
          "Already scored CONDITIONAL (7.5) - below BUY threshold of 8.25",
          "Announced April 2025 (8 months ago) - market aware",
          "Mobility only 11% of revenue (small tail)",
          "Value unlock ($5B-$8B) is only 3-5% of market cap - modest impact",
          "8-9 month wait to distribution",
          "Stock down -1% since initial screening",
          "13 analyst coverage - not overlooked opportunity"
        ]
      },
      "framework_limitation_note": "SPGI reinforces mega-cap boundary issue (same as HON, FDX). At $158.24B, this is the largest spinoff analyzed. Mobility representing only 11% of revenue further reduces catalyst materiality. Framework designed for smaller, underappreciated situations.",
      "notes": "RE-ANALYSIS: Previously screened 2025-12-30 with 7.5 CONDITIONAL score. Distribution targeted late 2026 (Oct-Nov). Framework fit WEAK due to mega-cap size, small spinoff percentage (11%), and 8-month-old announcement. This is an institutional play tracked by all major funds, not an idiosyncratic opportunity. Lowest priority among all spinoffs analyzed."
    },
    {
      "date": "2026-01-02",
      "ticker": "AQST",
      "company": "Aquestive Therapeutics, Inc.",
      "archetype": "pdufa",
      "event_id": "EVT-2026-001",
      "additional_event_id": "EVT-2026-003",
      "kill_screens_passed": false,
      "failed_screens": [
        {
          "screen": "Altman Z-Score",
          "value": -5.39,
          "threshold": 1.5,
          "operator": ">=",
          "result": "SEVERE FAIL - Z-Score of -5.39 << 1.5 biotech-adjusted threshold, indicates extreme financial distress",
          "source": "Framework schema (kill_screens.json line 166-173)",
          "severity": "critical",
          "context": "Z-Score below zero indicates severe distress. AQST's -5.39 is catastrophic even for biotech."
        },
        {
          "screen": "PDUFA Financial Health - Debt/Equity",
          "value": "Unknown (likely >0.75)",
          "threshold": 0.75,
          "operator": "<",
          "result": "LIKELY FAIL - Multiple sources cite 'formidable debt-to-equity challenge' and 'debt-ridden balance sheet'",
          "source": "Web search / financial analysis",
          "severity": "high"
        },
        {
          "screen": "PDUFA Financial Health - Cash Runway",
          "value_months": "15-25",
          "threshold_months": 18,
          "operator": ">=",
          "result": "BORDERLINE - Company guidance says cash funds 'through launch and into 2027' (~15-21 months from Q3 2025)",
          "source": "Q3 2025 earnings release / financial analysis",
          "severity": "medium",
          "calculation": "Cash $129.1M / monthly burn $5.1M = ~25 months (calculated), but company guidance suggests 15-21 months"
        }
      ],
      "passed_screens": [
        {
          "screen": "Market Cap Ceiling",
          "value": 788000000,
          "threshold": 50000000000,
          "operator": "<",
          "result": "PASS - $788M well below $50B threshold",
          "source": "Yahoo Finance"
        },
        {
          "screen": "Net Cash Position",
          "value": 84100000,
          "threshold": 0,
          "operator": ">",
          "result": "PASS - Net cash $84.1M (Cash $129.1M - Debt $45M)",
          "source": "Q3 2025 earnings / debt refinancing press release"
        }
      ],
      "result": "PASS",
      "reason": "Failed Altman Z-Score kill screen with catastrophic -5.39 score. Additionally failed PDUFA financial health screens for debt/equity ratio. Even with $85M equity raise in August 2025, company remains in severe financial distress.",
      "pass_decision_file": "trades/passed/AQST-20260102-PASS.json",
      "financial_summary": {
        "market_cap": "$788M",
        "current_price": "$6.46",
        "cash_q3_2025": "$129.1M",
        "total_debt": "$45M+ (13.5% senior notes due 2028)",
        "q3_revenue": "$12.8M",
        "q3_net_loss": "$15.4M",
        "fy2025_ebitda_loss_guidance": "$47-51M",
        "recent_financing": "$85M equity offering closed Aug 15, 2025",
        "analyst_consensus": "Strong Buy (6 analysts) with $8.83 target (+36.7%)"
      },
      "pdufa_details": {
        "catalyst_1": "FDA decision on AQST-109 (epinephrine) - Jan 6, 2026",
        "catalyst_2": "FDA decision on Anaphylm (epinephrine sublingual film) - Jan 31, 2026",
        "days_to_catalyst": 4,
        "no_adcom_required": true,
        "base_approval_rate": "92% post-NDA",
        "market_size": "$8B epinephrine market"
      },
      "framework_assessment": "Exemplar case of why financial kill screens exist. Despite 92% PDUFA approval rate, stellar analyst support (+37% upside), and no AdCom requirement, the Z-Score of -5.39 disqualifies AQST. Even with approval, commercialization costs strain balance sheet. CRL would likely trigger dilutive financing or bankruptcy. Principal debt repayments start June 2026 (6 months post-PDUFA), creating time pressure. Framework prioritizes capital preservation over catalyst quality.",
      "lessons_learned": [
        "Z-Score -5.39 overrides all bullish factors (92% approval rate, analyst consensus)",
        "PDUFA financial health screens caught the risk that generic Z-Score flagged",
        "$85M equity raise in Aug 2025 insufficient to cure balance sheet distress",
        "13.5% debt cost with June 2026 principal repayments creates existential timeline pressure",
        "Analysts can be bullish (Strong Buy, +37%) while framework screens show unacceptable risk"
      ],
      "tags": [
        "pdufa",
        "biotech",
        "kill_screen_fail",
        "z_score_catastrophic",
        "financial_distress",
        "high_debt",
        "cash_runway_borderline",
        "january_2026_catalyst"
      ],
      "notes": "AQST has TWO PDUFA catalysts in January 2026 (Jan 6 and Jan 31) with 92% historical approval rate and no AdCom required. Despite bullish setup, Z-Score of -5.39 is disqualifying. Company raised $85M in August 2025 but still shows severe financial distress. Framework screens override market optimism. Alternative: Screen TVTX (EVT-2026-002, Jan 13 PDUFA) for potentially better financial health."
    }
  ]
}
